ImmuCell Corporation — Q2 2014 Form 10-Q
Reporting period: Three and six months ended June 30, 2014; unaudited. ImmuCell develops, manufactures and sells animal-health products for dairy and beef industries. First Defense is its lead product; Mast Out, a treatment for subclinical mastitis, remains in development and subject to regulatory approval.
Financial results and liquidity
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Product sales | $1.540 million | $1.366 million | $3.621 million | $3.213 million |
| Gross margin | $879,000; 57% | $784,000; 57% | $2.028 million; 56% | $1.837 million; 57% |
| Operating income (loss) | $(459,000) | $24,000 | $(446,000) | $350,000 |
| Net income (loss) | $(295,000); $(0.10) per share | $6,000; approximately $0.00 per share | $(308,000); $(0.10) per share | $211,000; $0.07 per share |
| Operating cash flow | Not separately stated | Not separately stated | $330,000 | $935,000 |
Six-month product sales rose 13% year over year, while operating expenses rose 66% to $2.475 million, largely reflecting increased product-development spending. Cash and cash equivalents were $1.701 million at June 30, down from $2.270 million at year-end. Cash, cash equivalents and investments totaled $5.182 million, versus $5.255 million at year-end. Net working capital was approximately $5.483 million, down 17%.
Outstanding bank debt was approximately $993,000, including $195,000 current and $798,000 long-term; the $500,000 credit line was unused. The company reported compliance with loan covenants. Total liabilities were $1.664 million and stockholders’ equity was $9.103 million. Six-month capital expenditures were $313,000. Net cash decreased $570,000.
Changes, outlook and material developments
- First Defense sales increased 21% in Q2 and 12% for the first half; it accounted for 90% of first-half product sales. Topical-wipe sales increased 26% overall, supported by 159% growth in Preva pet wipes, while Wipe Out Dairy Wipes sales fell 12%. CMT sales were nearly flat.
- Product-development expenses increased $817,000 to $1.355 million for the first half. About $913,000 related to facility modifications and processing equipment for pharmaceutical-grade Nisin for Mast Out; management described these costs as non-recurring, infrequent and unusual.
- The company reported that it expected second-half 2014 profitability, but still expected a full-year 2014 net loss. It expected gross margin to remain above 50% during 2014 and anticipated continued First Defense sales growth. First Defense price increases took effect August 1, 2014; added sales staff were expected to raise the sales-and-marketing expense ratio temporarily to 20%–24%, with a goal of below 20% in 2015.
- A roughly $3 million facility investment supports increased capacity, cGMP compliance and pharmaceutical-grade Nisin production. The Nisin facility modifications were substantially completed at the start of Q3 2014; a separate 7,200-square-foot building addition was expected to be completed in Q4 2014. At June 30, the filing reported $1.241 million spent or accrued across the projects, with $1.759 million remaining in the budget.
- For Mast Out, three of five FDA technical sections were complete. Management targeted completion of the Human Food Safety section in 2015 and first submission of the Chemistry, Manufacturing and Controls section in late 2014 or early 2015. It estimated potential FDA approval and test marketing in the first half of 2016, contingent on completing regulatory requirements. The company had suspended active partner pursuit while advancing approval independently, but may need external financing, a partner or another commercial arrangement for expanded manufacturing.
- A second pivotal study of a rotavirus-related calf product began in Q2 2014; enrollment was expected to finish around year-end, with potential USDA approval in 2015 if results were positive.
Risks, contingencies and other items
- Mast Out approval, timing, commercial acceptance, manufacturing economics and financing are uncertain. A larger-scale Nisin manufacturing facility could require substantial additional funding; an earlier estimate for a facility was approximately $13 million.
- Customer concentration is significant: two distributors accounted for 61% of first-half sales, and 51% of trade receivables at June 30. First Defense dependence, distributor consolidation, competition, raw-material supply, seasonal demand and volatile dairy and beef economics also pose risks.
- The company held $5.182 million in cash and investments, but management’s liquidity outlook depends partly on ongoing product sales and execution of development and facility plans. Management stated resources were sufficient for working capital and operations for at least the next 12 months.
- The $500,000 line of credit was extended through May 31, 2015 and was unused. Mortgage debt is effectively fixed at 6.04% through an interest-rate swap; a $451,885 balloon payment is due in 2020.
- The board extended the Common Stock Rights Plan through September 19, 2017. The filing reported no legal proceedings and no material change in internal control over financial reporting; management concluded disclosure controls were effective.
Investor verification priorities
- Track whether expected second-half profitability and the full-year loss outlook match subsequent results, including the timing and nature of elevated development costs.
- Verify Mast Out FDA-section submissions and completion, study and manufacturing validation progress, approval timing, and funding or partnering needs.
- Compare facility-project spending, remaining budget, completion dates and production yields against management’s plans.
- Monitor First Defense growth, gross margin, customer and receivable concentration, and any effects of the August 2014 price increase.
- Review liquidity, operating cash generation, capital expenditures, debt repayment and covenant compliance as the development program proceeds.